Phase 3 Readout
KPTI: Phase 3 Topline: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) Wi
December 1, 2026 · rituximab-gemcitabine-dexamethasone-platinum. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 1, 2026
- Company
- Karyopharm Therapeutics Inc. (KPTI)
- Drug
- rituximab-gemcitabine-dexamethasone-platinum
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) Wi
- Drug
- rituximab-gemcitabine-dexamethasone-platinum
- Indication
- Relapsed/Refractory Diffuse Large B-cell Lymphoma